News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

PHARMAC widening access for Truvada

PHARMAC widening access for Truvada for the prevention of HIV infection

7 February 2018

A decision to widen access to Truvada to prevent infection with HIV is a great opportunity to reduce transmission rates of HIV infections in New Zealand, says PHARMAC Chief Executive Sarah Fitt.

From 1 March 2018 emtricitabine with tenofovir disoproxil fumarate (Truvada) will be funded for the prevention of HIV infection (a treatment known as pre-exposure prophylaxis, or PrEP). Truvada is already funded for treating people infected with HIV, however this decision means it will also be funded for people if they are not infected but are at a high risk of contracting HIV.

PHARMAC estimates up to 4000 people with a high risk of contracting HIV will be eligible for PrEP treatment, which has the potential to almost completely eliminate the risk of HIV infection. New Zealand will be one of the first countries in the world to publicly fund PrEP for the prevention of HIV.

“Together with safe sex practise, early diagnosis and access to treatment, we expect that PrEP will significantly reduce HIV transmission rates in New Zealand,” says Ms Fitt.

“Truvada was registered for PrEP in August 2017, and we have worked closely with the New Zealand AIDS Foundation to support them in preparing a funding application for PrEP, which was reviewed by our clinical advisers and given a high priority for funding in November 2017.

“Condoms continue to be the primary and recommended method of preventing transmission of HIV and other sexually transmitted infections. Condoms are fully funded on prescription and are highly effective, but rates of HIV infection are still increasing in New Zealand.”

Funded access to PrEP will require that people undergo regular testing for HIV and other sexually transmitted infections, and are monitored for risk of side effects. People taking funded PrEP will receive advice on ways to reduce the risk of HIV and sexually transmitted infections.

For more information on this decision, visit the PHARMAC website.
Notification - https://www.pharmac.govt.nz/news/news/notification-2018-02-07-prep/
Information about getting funded PrEP - https://www.pharmac.govt.nz/prep

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Howard Davis: Three Reasons for Film Fans to Get Netflix

The past two months have finally seen Netflix come into its own, providing the financing for three films that will warm the hearts of cinephiles everywhere - Orson Welles' The Other Side of The Wind, The Coen Brothers' The Ballad of Buster Scruggs, and Alfonso Cuarón's Roma. More>>


Scoop Review Of Books: The Rift by Rachael Craw

Rachael Craw's first series, Spark has been extremely well received by the YA community in both Australia and New Zealand (it has a hashtag, #SparkArmy), and The Rift looks like it’s going to be just as popular. More>>



Porn And Teens Report: 'Wake-Up Call' On Sexuality Education

Family Planning: The Office of Film and Literature Classification’s survey of more than 2000 young people about pornography highlights that sexuality education provides an opportunity for a vital counter-narrative to porn that could reach most young New Zealanders... More>>

ALSO:


 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland